Article Per Year (5 Year)
p-Index From 2021 - 2026
1.665
P-Index
This Author published in this journals
All Journal Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan Biomedika Universa Medicina Communications in Science and Technology Jurnal Kedokteran Universitas Palangka Raya JKKI : Jurnal Kedokteran dan Kesehatan Indonesia jpki Indonesian Journal of Pharmacology and Therapy Berkala Ilmiah Kedokteran dan Kesehatan Masyarakat Cermin Dunia Kedokteran
Ninda Devita, Ninda
Mahasiswa Fakultas Kedokteran Universitas Islam Indonesia
Biochemistry, Genetics & Molecular Biology Engineering Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 12 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 12 Documents
Search

 1   2 
Tinjauan Imunologi pada Fenomena Non-Responder terhadap Vaksinasi Hepatitis B: Analisis Arjana, Adika Zhulhi; Devita, Ninda
Cermin Dunia Kedokteran Vol 52 No 4 (2025): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v52i4.1437

Abstract

Hepatitis B vaccine has been highly effective in preventing HBV infection. However, a subset of individuals fails to develop adequate protective antibodies after complete vaccination series (anti-HBs ≥ 10 mIU/mL), termed as non-responders. Non-responder phenomenon is influenced by a complex interplay of genetic, immunological, and environmental factors. This narrative review aims to delve into the immunological aspects of the non-responder phenomenon, exploring the factors influencing vaccine response, the immunological mechanisms involved, and potential approaches to managing and overcoming non-responders.
Clinical application of dendrimer in cancer and COVID-19 therapy: a review Devita, Ninda; Nurfadilah; Siti Khadijah; Ulil Albab Habibah
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2311

Abstract

Dendrimers are nanoparticles with unique characteristics. These characteristics allow these nanoparticles to be widely applied in medicine. It can be used as a therapy for various types of cancer. The dendrimers can also been use an alternative to accelerating the diagnosis and therapy of COVID-19. This review aimed to delve deeper into the myriad clinical applications of dendrimers in the treatment of various cancers and its potential use for the treatment or diagnosis of COVID-19. The databases used for this review were Google Scholar and Science Direct. The inclusion criteria for this review are articles published in 2018-2023. Articles other than the original articles and reviews we excluded from the study. Anticancer formulated in dendrimers have a better ability to eradicate cancer cells in the treatment of breast, colon, lung, prostate, skin, ovarian, and liver cancers compared to ordinary anticancer agents. Dendrimer in vivo, in vitro and phase II clinical trials can be used to deliver miRNA therapy or symptomatic drugs in COVID-19 patients and as vaccine delivery agents. The quality of molecular diagnosis of COVID-19 can also be improved with these nanoparticles. The use of dendrimers can improve the quality of management of cancer and COVID-19 patients.
Co-Authors Adika Zhulhi Arjana Anisa Rachmawati, Anisa Ariasti, Nia Eko Andriyanto Farida Juliantina Rachmawaty Habibah, Ulil Albab Ika Fidianingsih Irfan, Rozan Muhammad Juliantina Rachmawaty, Farida Khoiriyah, Umatul Marufi, Rian Muhammad, Afivudien Nurfadilah Nurmasitoh, Titis Rina Susilowati Riski, Muhammad Syafiq Siti Khadijah Ulil Albab Habibah Umi S. Intansari Ida Savitri Laksanawati Yuantari, Rahma